Grünenthal GmbH and Kyowa Kirin Co. have successfully formed a joint venture collaboration to create a new entity named Grünenthal Meds. This collaboration involves a portfolio of 13 brands spanning six therapeutic areas, with a primary focus on pain management medicines. Notable products in the portfolio include Abstral and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis. These medications will continue to be marketed through affiliates in major European countries and a network of partners in various global territories. Grünenthal, a leading global player in pain management, holds a majority share of 51 percent, and they plan to acquire the remaining 49 percent share by exercising an option in early 2026. The partnership aims to extend patient access to life-changing medications and enhance pain relief for those in need.
Global News and Digital Insights
for the Healthcare Industry
Menu
